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The prognostic role of specific biomarkers of the renin-angiotensin-aldosterone system and
sympathetic activation pathways in heart failure has never been investigated in populations
with current evidence-weighted treatment. To establish whether the plasma renin activity
(PRA), among several neurohormonal biomarkers, is able to predict cardiac events in a
population of patients with heart failure on up-to-date treatment, we selected 996 consec-
utive patients with systolic left ventricular dysfunction (ejection fraction <50%, mean age
65  13 years), who underwent a complete clinical and humoral characterization and were
then followed up (median 36 months, range 0 to 72) for cardiac death and appropriate
implantable cardioverter device shock. We recorded 170 cardiac deaths and 27 shocks. On
Cox multivariate analysis, only ejection fraction (hazard ratio 0.962, 95% confidence
interval 0.938 to 0.986), N-terminal pro-brain natriuretic peptide (NT-proBNP; hazard
ratio 1.729, 95% confidence interval 1.383 to 2.161) and PRA (hazard ratio 1.201, 95%
confidence interval 1.024 to 1.408) were independent predictors of cardiac death. Receiver
operating characteristic curve analysis identified a cutoff value for PRA of 2.30 ng/ml/hour
that best predicted cardiac mortality. Independent predictors of PRA were ejection frac-
tion, functional class, sodium, potassium, NT-proBNP, norepinephrine, aldosterone, C-re-
active protein, and medical therapy. The association of high NT-proBNP and high PRA
identified a subgroup (22% of the study population) with the greatest risk of cardiac death.
In conclusion, PRA resulted an independent prognostic marker in patients with systolic
heart failure additive to NT-proBNP level and ejection fraction. PRA might help to select
those patients needing an enhanced therapeutic effort, possibly targeting incomplete renin-
angiotensin-aldosterone system blockade. © 2011 Elsevier Inc. All rights reserved. (Am J
Cardiol 2011;108:246–251)
o
tThe aim of the present study was to establish whether
plasma renin activity (PRA) is able to predict cardiac events
in patients with heart failure (HF), among a number of
clinical and functional parameters and neurohormonal bio-
markers in a population of patients with HF receiving up-
to-date pharmacologic and device treatment.
Methods
From June 2002 to November 2008, we prospectively
enrolled 996 consecutive patients with systolic dysfunction
(left ventricular ejection fraction [EF] 50%), referred to
our division for HF management. The diagnosis of HF was
determined by the history, symptoms, physical examination,
and instrumental findings for the assessment of structural
myocardial involvement. Cardiac morphology and function
were assessed by 2-dimensional Doppler echocardiography.
Acute coronary syndrome within 6 months before the
enrollment was the only exclusion criterion. The character-
istics of the sample population are summarized in Table 1.
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002-9149/11/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
oi:10.1016/j.amjcard.2011.03.034All patients were at the maximum tolerated dose of 
blockers, angiotensin-converting enzyme inhibitors/angio-
tensin receptor blockers (ACEIs/ARBs), and aldosterone
antagonists and had a controlled dietary sodium daily intake
(4 g NaCl). The study protocol was performed according
to the Declaration of Helsinki and was approved by the
institutional ethics committee, and all subjects provided
informed consent.
All patients underwent a comprehensive biohumoral char-
acterization. Blood samples were drawn at 8.00 A.M. after an
vernight fast, according to a standardized experimental pro-
ocol.1 Follow-up started with blood sampling and continued
until study termination (i.e., May 2009). Independent inter-
viewers obtained follow-up data directly from the patients,
relatives, institute cardiologists, or general practitioners.
Information about the time and cause of death was obtained
from death certificates, postmortem reports, and family doc-
tors. The primary end point was cardiac death (further
distinguished into death from HF progression and sudden
death). Appropriate implanted cardioverter defibrillator
shocks and sudden death were considered together as a
combined end point. Patients who died from noncardiac-
related causes or underwent heart transplantation or ventric-
ular assistance device implantation were considered cen-
sored at the event.
Statistical analysis was performed using the Statistical
Package for Social Sciences, version 13.0 (SPSS, Chicago,
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247Heart Failure/Plasma Renin Activity and PrognosisIllinois). The data are presented as the mean  SD or as the
median and interquartile range for values with a non-normal
distribution. Variables with a skewed distribution were log-
arithmically transformed for parametric analysis. Continu-
ous variables were compared using Student’s t test, and
discrete variables were compared using the chi-square test.
The candidate independent variables used on univariate Cox
proportional analysis for prognostic aims were selected by
their close association with the HF outcome. In particular,
we considered age, gender, body mass index, etiology of
cardiomyopathy (ischemic/nonischemic), New York Heart
Association class, echocardiographic indexes of left ventric-
ular function (EF), hemoglobin, estimated glomerular filtra-
tion rate using Cockroft-Gault’s formula, thyroid function
(free triiodothyronine), -glutammyl-transferase, neurohor-
ones (N-terminal pro-brain natriuretic peptide [NT-
roBNP], cortisol, epinephrine, norepinephrine, aldoste-
Table 1
Characteristics of overall population and subgroups with plasma renin act
Variable All Patie
(n  99
Age (years) 65  1
Gender
Men 747 (75%)
Women 249 (25%)
Body mass index (kg/m2) 26.6  4
Cardiomyopathy etiology
Ischemic 428 (43%)
Nonischemic 568 (57%)
New York Heart Association class
I–II 618 (62%)
III–IV 378 (38%)
trial fibrillation 179 (18%)
jection fraction (%) 32.9  9
End-systolic diameter (mm) 50  1
End-diastolic diameter (mm) 62  8
Left ventricular mass (g/m2) 146  3
Glomerular filtration rate (ml/min) 70.5  3
Hemoglobin (g/dl) 13.5  1
Free-triiodothyronine (pg/ml) 2.4  0
Free thyroxine (pg/ml) 12.90  5
Thyroid stimulating hormone (uUI/ml) 2.55  3
N-terminal pro-brain natriuretic peptide (ng/L) 1,329 (467–
Epinephrine (ng/L) 30 (13–5
Norepinephrine (ng/L) 520 (342–
Plasma renin activity (ng/ml/hour) 1.59 (0.43–
Aldosterone (ng/L) 145 (86–2
Medications
 Blockers 817 (82%)
ngiotensin-converting enzyme inhibitors/angiotensin
receptor blockers
827 (83%)
pironolactone 598 (60%)
urosemide 807 (81%)
itrates 289 (29%)
ardiac resynchronization therapy 90 (9%)
ardiac resynchronization therapy and defibrillator 129 (13%)
mplanted cardioverter device 70 (7%)
Data are presented as mean  SD for continuous normally distributed va
ariables, or n (%).one, and PRA), and therapy with diuretics, nitrates, blockers, ACEIs/ARBs, and spironolactone. All the vari-
ables found to be significant on univariate analysis were
included in the multivariate Cox proportional hazards
model. The optimal cutpoints for PRA and NT-proBNP
were quantified using receiver operating characteristic
curves. The prognostic value of the spectrum of PRA levels
was assessed with the P-spline method,2 fitting data to a set
of spline basis functions with a reduced set of knots, com-
bined with the roughness penalty of smoothing splines. The
Kaplan-Meier life table, estimating cardiac-related death,
was used to summarize the follow-up experience in the
patient population. Differences in survival curves were
tested with the log-rank test (Mantel-Cox). The same vari-
ables used for the survival analysis were entered into the
univariate linear regression analysis to examine the associ-
ation with PRA, together with the serum glucose, sodium,
potassium, thyroid-stimulating hormone, and C-reactive
RA) values 2.3 or 2.3 ng/ml/hour cutpoint
PRA p Value
(Low vs High)
Low
(n  585)
High
(n  411)
65  13 65  12 0.892
0.970
438 (75%) 308 (75%)
147 (25%) 103 (25%)
26.7  4.6 26.5  5.1 0.562
0.003
228 (39%) 197 (48%)
357 (61%) 214 (52%)
0.001
404 (69%) 214 (52%)
181 (31%) 197 (48%)
94 (16%) 78 (19%) 0.630
34.8  9.4 30.2  9.8 0.001
48  9 52  11 0.001
61  8 63  9 0.001
146  38 145  36 0.957
73.0  32.6 66.9  35.6 0.005
13.60  1.77 13.44  1.70 0.166
2.44  1.08 2.37  0.72 0.287
12.27  4.90 13.79  5.50 0.001
2.40  2.75 2.76  4.99 0.197
1,116 (418–2,939) 1,682 (553–4,086) 0.001
27 (11–48) 33 (19–61) 0.001
457 (302–659) 602 (425–951) 0.001
0.56 (0.20–1.20) 6.11 (3.87–10.72) 0.001
117 (72–176) 190 (113–319) 0.001
474 (81%) 341 (83%) 0.464
486 (83%) 337 (82%) 0.202
304 (52%) 296 (72%) 0.001
439 (75%) 358 (87%) 0.001
176 (30%) 111 (27%) 0.392
59 (10%) 33 (8%) 0.092
53 (9%) 74 (18%) 0.001
41 (7%) 29 (7%) 0.909
median (25th to 75th percentiles) for continuous non-normally distributedivity (P
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248 The American Journal of Cardiology (www.ajconline.org)tered into the multivariate linear regression analysis. A p
value 0.05 was considered significant.
Results
During a median follow-up of 36 months (range 0 to 72),
290 deaths occurred. Of the 290 patients who died, 170 died
from cardiac causes (124 from associated HF progression,
26 from sudden death, 15 from acute myocardial infarction,
and 5 perioperative), and 27 implanted cardioverter defibril-
Figure 1. PRA P-spline hazard ratio plot for cardiac mortality. Curve shows
exponential behavior with risk increasing for greater PRA. Vertical line
indicates PRA value corresponding to 2.3 ng/ml/hour cutpoint.
Table 2
Univariate and multivariate analysis of predictors for cardiac mortality
Variable
Hazard Ra
Age 1.257 (1.
Body mass index 0.826 (0.
ew York Heart Association class 3.855 (2.
jection fraction 0.693 (0.
tiology (ischemic) 1.746 (1.
ree triiodothyronine 0.755 (0.
emoglobin 0.803 (0.
lomerular filtration rate 0.647 (0.
ortisol 1.193 (1.
-Glutamyltransferase 1.155 (1.
-terminal pro-brain natriuretic peptide 1.860 (1.
lasma renin activity 1.293 (1.
pinephrine 1.227 (1.
orepinephrine 1.308 (1.
ldosterone 1.127 (1.
ngiotensin-converting enzyme inhibitors/angiotensin
receptor blockers
0.532 (0.
pironolactone 1.761 (1.
itrates 1.699 (1.
urosemide 2.352 (1.
Data are presented as median (range).lator shocks were observed. Five patients underwent hearttransplantation and one ventricular assist device implanta-
tion, as destination therapy.
On Cox univariate analysis age, body mass index, New
York Heart Association class, EF, etiology of cardiomyop-
athy, free triiodothyronine, hemoglobin, estimated glomer-
ular filtration rate, cortisol, -glutammyl-transferase, NT-
roBNP, PRA, epinephrine, norepinephrine, aldosterone,
nd therapy with ACEIs/ARBs, spironolactone, nitrates, or
iuretics were predictors of cardiac death. On multivariate
nalysis, only EF, NT-proBNP, and PRA were independent
redictors of cardiac death (Table 2).
On receiver operating characteristic analysis, the cutoff
alue of 2.30 ng/ml/hour for PRA best predicted cardiac
ortality (area under the receiver operating characteristic
urve 0.649; sensitivity 59%, specificity 62%). An in-
reased risk of cardiac mortality in terms of the hazard ratio
hazard ratio 1) at P-spline analysis (Figure 1) was ob-
erved for PRA levels of 1.8 ng/ml/hour.
As listed in Table 1, patients with PRA levels 2.30
ng/ml/hour had a greater New York Heart Association func-
tional class, presented more frequently with ischemic dys-
function, had worse left ventricular EF and greater left
ventricular diameters, lower estimated glomerular filtration
rate, and greater plasma NT-proBNP, epinephrine, norepi-
nephrine, and aldosterone levels. Patients with greater PRA
were also more frequently treated with spironolactone and
furosemide and device therapy.
As shown in the Kaplan-Meier analysis, patients with
PRA 2.30 ng/ml/hour had a much greater rate of cardiac
death, death from HF progression, and the composite end
point of sudden death plus implanted cardioverter defibril-
lator shock (Figure 2). The use of drugs exerting renin-
angiotensin-aldosterone system antagonism did not alter the
riate Model Multivariate Model
CI) p Value Hazard Ratio (95% CI) p Value
79) 0.001 — —
08) 0.001 — —
56) 0.001 — —
58) 0.001 0.962 (0.938–0.986) 0.002
87) 0.001 — —
95) 0.001 — —
71) 0.001 — —
24) 0.001 — —
55) 0.001 — —
43) 0.001 — —
57) 0.001 1.729 (1.383–2.161) 0.001
01) 0.001 1.201 (1.024–1.408) 0.024
25) 0.001 — —
19) 0.001 — —
23) 0.004 — —
63) 0.001 — —
83) 0.001 — —
61) 0.002 — —
08) 0.002 — —Univa
tio (95%
146–1.3
751–0.9
775–5.3
634–0.7
278–2.3
671–0.8
740–0.8
579–0.7
134–1.2
073–1.2
682–2.0
194–1.4
136–1.3
205–1.4
038–1.2
371–0.7
249–2.4
223–2.3
380–4.0prognostic value of PRA.
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249Heart Failure/Plasma Renin Activity and PrognosisOn receiver operating characteristic analysis, the optimal
cutpoint for plasma NT-proBNP was 1,581 ng/L (area under
the curve 0.765, sensitivity 66%, specificity 60%) for car-
Figure 2. Kaplan-Meier survival analysis for cardiac mortality (A), death fr
ardioverter defibrillator shock (C) in patients according to 2.3-ng/ml/hou
Figure 3. Kaplan-Meier survival curves for cardiac death in 4 subsets
identified according to cutpoint values of 2.3 ng/ml/hour for PRA and
1,581 ng/L for NT-proBNP; p  NS for low NT-proBNP/low PRA
versus low NT-proBNP/high PRA; p 0.001 for all other comparisons.diac mortality. As shown in Figure 3, the association of highNT-proBNP and high PRA identified a subgroup of 215
patients (22% of the study population) with the greatest risk
of cardiac death.
On univariate analysis, an increased PRA level was as-
sociated with EF, New York Heart Association functional
class, cardiomyopathy etiology, estimated glomerular filtra-
tion rate, glucose, plasma sodium and potassium, cortisol,
NT-proBNP, epinephrine, norepinephrine, aldosterone,
-glutammyl-transferase, C-reactive protein, and therapy
with ACEIs/ARBs, spironolactone, and furosemide. On
multivariate analysis, only EF (R  0.26, p  0.001), New
York Heart Association class (R  0.20, p  0.006), so-
ium (R  0.41, p 0.001), potassium (R  0.09, p 
.018), NT-proBNP (R  0.11, p 0.001), norepinephrine
R  0.34, p 0.001), aldosterone (R  0.39, p 0.001),
-reactive protein (R  0.13, p  0.042), and therapy with
pironolactone (R  0.29, p  0.002) and ACEIs/ARBs
R  0.08, p  0.002) were independent predictors of high
RA (R2  0.62 for the total model).
Discussion
In the present prospective series of patients with systolic
HF, PRA and NT-proBNP, together with EF, showed an
independent, additive, predictive value for cardiac death,
among a comprehensive panel of neurohormonal and clin-
ical biomarkers. Several variables independently predicted
PRA, suggesting the involvement of diverse mechanisms
accounting for its prognostic power.
Since the neurohormonal hypothesis,3 the search for ba-
sic pathophysiologic mechanisms of HF progression has
progression (B), and composite end point of sudden death plus implanted
int. High PRA  2.3 ng/ml/hour; low PRA  2.3 ng/ml/hour.om HFshifted from hemodynamics to peripheral feedback systems
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250 The American Journal of Cardiology (www.ajconline.org)and to neuroendocrine factors. Pioneering work by Cohn et
al and others has highlighted the prognostic relevance of the
plasma norepinephrine level and renin activity4–10; thus,
neurohormonal antagonism with  blockers, ACEIs, ARBs,
and spironolactone has become a cornerstone of treat-
ment,11 together with electrical therapy12 and aerobic train-
ng,13 all able to blunt neurohormonal activation in HF.
B-type natriuretic peptides are currently considered the
best prognosticators in HF among neuroendocrine biomark-
ers.14 Nonetheless, as markers of ventricular overload and
myocyte stress, they are also nonspecific15; thus, biomark-
rs more directly linked to causal pathways would be de-
ired for multimarker prognostic stratification strategy of
atients with HF.
Renin-angiotensin system activation, as assessed by
RA, holds a pivotal pathophysiologic meaning in HF, as
ndicated by several effects on ventricular remodeling, he-
odynamics, and renal function, through angiotensin II and
ldosterone production.16–20 Although biomarkers of sev-
ral neurohormonal axes examined (i.e., sympathetic ner-
ous system, thyroid, adrenal gland) were univariate pre-
ictors in our analysis, PRA independently predicted the
ccurrence of cardiac death in the systolic HF population
nd identified, among patients with a high NT-proBNP
evel, a consistent subgroup (22% of the whole population)
ith a markedly increased risk of cardiac death.
In the present study, PRA was assayed in patients mostly
reated with  blockers, diuretics, ACEIs/ARBs, and aldo-
sterone antagonists, all known to influence PRA. Our results
have shown that PRA elevation, owing to the intrinsic
mechanisms of disease progression and/or a rebound in-
crease secondary to ACEIs, ARBs, or spironolactone ther-
apy might significantly affect the disease evolution and
clinical outcome, either directly (through renin effects on
prorenin/renin receptors) or indirectly (through the stimula-
tion of angiotensin II and aldosterone synthesis), depicting,
as for ACE or aldosterone, the frame of a “PRA escape.”
A combined assay of PRA and NT-proBNP might
identify a significant proportion of patients with HF with
incomplete neuroendocrine antagonism using current
pharmacologic treatment, who would potentially benefit
by additional, enhanced, or differential therapeutic strate-
gies for renin-angiotensin-aldosterone system antagonism.
This seems even more worthwhile given the current/future
availability of new drugs acting on the renin-angiotensin-
aldosterone system cascade, such as direct renin inhibi-
tors,21,22 known to reduce PRA (but whose effect on patient
outcome is still unknown), or aldosterone synthase inhibi-
tors, still under experimental investigation.23 PRA might be
aluable as either a prognostic marker or a potential thera-
eutic target.
Our findings have confirmed and extended the results
rom previous studies by Latini et al7 and Masson et al,24 in
subset of patients with HF from the Valsartan Heart
ailure Trial (Val-HeFT) study. However, the patients en-
olled in these studies were undertreated in terms of the use
f  blockers and spironolactone compared to current indi-
ations. In particular, the relatively low rate (36%) of
-blocker therapy (blunting the adrenergic stimulatory ef-
fect on renin release)25,26 might explain the greater medianPRA level observed in both studies (5.26, interquartile
range 1.62 to 16.36 ng/ml/hour).
Given the value of PRA in predicting cardiac mortality
and its key role in assessing the degree of renin-angiotensin-
aldosterone system activation, a main pathway in HF pro-
gression, we investigated which clinical and neurohormonal
variables influenced its level more. Our results identified
EF, New York Heart Association class, sodium, potassium,
NT-proBNP, norepinephrine, aldosterone, C-reactive pro-
tein, and therapy with ACEIs/ARBs and spironolactone as
predictors of PRA, suggesting that it is affected by both
cardiac and systemic factors and influenced by renin-ang-
iotensin-aldosterone system antagonist drugs.27 In particu-
lar, the close relation found between PRA and aldosterone
level can be explained by a feedback mechanism, associated
with the stimulatory effect of aldosterone on renin and ACE
gene expression,28,29 as well as by a feed-forward mecha-
ism, through the aldosterone escape phenomenon (i.e.,
ldosterone synthesis stimulation by alternative biochemical
aths, such as chymases), in patients receiving ACEIs/
RBs therapy.30
As a possible limitation, preanalytical and analytic issues
are known to affect catecholamine and plasma renin assay,
although a rigorous, standardized protocol of blood sam-
pling and sample assay minimized every potential interfer-
ence in our setting.
In conclusion, our results have indicated that PRA has an
independent prognostic value in patients with systolic HF,
irrespective of medical treatment, additive to NT-proBNP
level and EF and could thus be used along side other
currently available biohumoral markers in the multimarker
strategy of HF prognostic stratification. Furthermore, PRA,
playing a central role in renin-angiotensin-aldosterone sys-
tem feedback regulation, as well as in the development of
pathophysiologic and clinical features of HF syndrome,
might help in selecting those patients needing an enhanced
therapeutic effort, possibly targeting incomplete renin-ang-
iotensin-aldosterone system blockade. The prognostic role
of PRA should be confirmed in larger populations and in
different settings (e.g., diastolic HF). Finally, it would be of
interest to investigate the effects of drugs directly affecting
renin enzymatic activity (e.g., direct renin inhibitors) on
both PRA and prognosis in patients with HF.
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